25-27 August in Boston, USA
Latent Labs’ launch to develop biologics using advanced AI models, alongside Eli Lilly’s Tunelab partnering with BigHat Bio and Chai Discovery, and Bayer’s collaboration with Cradle on AI-enabled antibody discovery, signals a step-change in industry sentiment.
AI use cases in pharma have shifted from pilots to strategic deployment, increasingly serving as an accelerant for re-architecting biologics discovery and expanding conventional computational toolkits to expedite lead candidate progression.
Formerly titled the CDD for Biologics Summit, this year’s CDD & AI for Biologics Summit has been re-envisioned to reflect the growing role of AI/ML in supercharging computational approaches for biologics design, property prediction and developability optimization.
Hear directly from wet-lab experimentalists and dry-lab experts to gain the insights needed to leverage the AI/ML and computational intersection, to design truly innovative biologics, achieve multi-objective optimisation and advance AI-enabled biologics with derisked CMC.
